[SCHEDULE 13G/A] Compass Therapeutics, Inc. SEC Filing
MPM BioImpact LLC reports beneficial ownership of 5,622,505 shares of Compass Therapeutics common stock, equal to 4.1% of the class. The filing states the reporting person has sole voting power and sole dispositive power over the reported shares and identifies the filer as an investment adviser (IA). The filer certifies the securities are held in the ordinary course of business and not to change or influence control of the issuer. Because the stake is below 5%, this Schedule 13G/A reflects a passive, non-control disclosure under the Exchange Act.
MPM BioImpact LLC segnala la titolarit脿 beneficiaria di 5,622,505 azioni ordinarie di Compass Therapeutics, pari al 4.1% della classe. Il deposito indica che il soggetto segnalante detiene il pieno diritto di voto e il pieno potere dispositvo sulle azioni segnalate e identifica il presentatore come consulente d'investimento (IA). Il presentatore certifica che i titoli sono detenuti nell'ordinaria attivit脿 di impresa e non con l'intento di modificare o influenzare il controllo dell'emittente. Poich茅 la partecipazione 猫 inferiore al 5%, questo Schedule 13G/A rappresenta una comunicazione passiva di non-controllo ai sensi dell'Exchange Act.
MPM BioImpact LLC declara la propiedad beneficiaria de 5,622,505 acciones ordinarias de Compass Therapeutics, equivalentes al 4.1% de la clase. La presentaci贸n indica que la persona informante tiene el exclusivo poder de voto y el exclusivo poder de disposici贸n sobre las acciones reportadas e identifica al declarante como asesor de inversiones (IA). El declarante certifica que los valores se mantienen en el curso ordinario del negocio y no con la finalidad de cambiar o influir en el control del emisor. Dado que la participaci贸n es inferior al 5%, este Schedule 13G/A refleja una divulgaci贸n pasiva de no control conforme al Exchange Act.
MPM BioImpact LLC電� Compass Therapeutics 氤错喌欤� 5,622,505欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨溂氅�, 鞚措姅 頃措嫻 韥措灅鞀れ潣 4.1%鞐� 頃措嫻頃滊嫟瓿� 氤搓碃頃╇媹雼�. 鞝滌稖靹滊鞐愲姅 氤搓碃鞚胳澊 氤搓碃霅� 欤检嫕鞐� 雽�頃� 雼弲 鞚橁舶甓岅臣 雼弲 觳橂秳甓岇潉 氤挫湢頃橁碃 鞛堨溂氅� 鞝滌稖鞛愲ゼ 韴瀽鞛愲靷� (IA)搿� 鞁濍硠頃滊嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖鞛愲姅 頃措嫻 歃濌秾鞚� 韱奠儊鞝侅澑 鞓侅梾 瓿检爼鞐愳劀 氤挫湢霅橁碃 鞛堨溂氅� 氚滍枆須岇偓鞚� 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼鞚� 氙胳箻旮� 鞙勴暅 氇╈爜鞚� 鞎勲嫎鞚� 歃濍獏頃╇媹雼�. 歆�攵勳澊 5% 氙鸽鞚措瘈搿� 鞚� Schedule 13G/A電� Exchange Act鞐� 霐半ジ 靾橂彊鞝� 牍勳氚� 瓿店皽毳� 氚橃榿頃╇媹雼�.
MPM BioImpact LLC d茅clare la propri茅t茅 b茅n茅ficiaire de 5,622,505 actions ordinaires de Compass Therapeutics, soit 4.1% de la cat茅gorie. Le d茅p么t indique que la personne d茅clarant d茅tient le pouvoir de vote exclusif et le pouvoir de disposition exclusif sur les actions d茅clar茅es et identifie le d茅posant comme conseiller en investissements (IA). Le d茅posant certifie que les titres sont d茅tenus dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contr么le de l'茅metteur. 脡tant donn茅 que la participation est inf茅rieure 脿 5%, ce Schedule 13G/A constitue une divulgation passive sans contr么le en vertu de l'Exchange Act.
MPM BioImpact LLC meldet wirtschaftliches Eigentum an 5,622,505 Aktien der Stammaktien von Compass Therapeutics, entsprechend 4.1% der Klasse. Die Meldung besagt, dass die meldende Person alleinige Stimmrechte und alleinige Verf眉gungsmacht 眉ber die gemeldeten Aktien besitzt und identifiziert den Einreicher als Investmentberater (IA). Der Einreicher best盲tigt, dass die Wertpapiere im normalen Gesch盲ftsverlauf gehalten werden und nicht dazu dienen, die Kontrolle des Emittenten zu 盲ndern oder zu beeinflussen. Da die Beteiligung unter 5% liegt, stellt dieses Schedule 13G/A eine passive, nicht-kontrollierende Offenlegung nach dem Exchange Act dar.
- None.
- None.
Insights
TL;DR: MPM BioImpact reports a passive 4.1% stake (5.62M shares) in CMPX; this is informational and not a control move.
The filing discloses 5,622,505 shares owned representing 4.1% of Compass Therapeutics and confirms sole voting and dispositive power for those shares. Classification as an IA and the certification that holdings are in the ordinary course indicate a passive position consistent with Schedule 13G/A procedures. For investors, the disclosure documents institutional interest but does not signal a governance change given the sub-5% size and the stated non-control intent.
TL;DR: The report documents a non-control institutional holding of 4.1% with sole voting/dispositive power; governance impact is minimal.
Itemized reporting shows no shared power and affirms the position is not intended to influence control. The use of Schedule 13G/A and the Item 10 certification are consistent with a passive, disclosure-driven filing rather than an activist or control-oriented approach. From a governance perspective, the filing does not trigger control disclosures or group formation and should not materially alter board or shareholder dynamics by itself.
MPM BioImpact LLC segnala la titolarit脿 beneficiaria di 5,622,505 azioni ordinarie di Compass Therapeutics, pari al 4.1% della classe. Il deposito indica che il soggetto segnalante detiene il pieno diritto di voto e il pieno potere dispositvo sulle azioni segnalate e identifica il presentatore come consulente d'investimento (IA). Il presentatore certifica che i titoli sono detenuti nell'ordinaria attivit脿 di impresa e non con l'intento di modificare o influenzare il controllo dell'emittente. Poich茅 la partecipazione 猫 inferiore al 5%, questo Schedule 13G/A rappresenta una comunicazione passiva di non-controllo ai sensi dell'Exchange Act.
MPM BioImpact LLC declara la propiedad beneficiaria de 5,622,505 acciones ordinarias de Compass Therapeutics, equivalentes al 4.1% de la clase. La presentaci贸n indica que la persona informante tiene el exclusivo poder de voto y el exclusivo poder de disposici贸n sobre las acciones reportadas e identifica al declarante como asesor de inversiones (IA). El declarante certifica que los valores se mantienen en el curso ordinario del negocio y no con la finalidad de cambiar o influir en el control del emisor. Dado que la participaci贸n es inferior al 5%, este Schedule 13G/A refleja una divulgaci贸n pasiva de no control conforme al Exchange Act.
MPM BioImpact LLC電� Compass Therapeutics 氤错喌欤� 5,622,505欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨溂氅�, 鞚措姅 頃措嫻 韥措灅鞀れ潣 4.1%鞐� 頃措嫻頃滊嫟瓿� 氤搓碃頃╇媹雼�. 鞝滌稖靹滊鞐愲姅 氤搓碃鞚胳澊 氤搓碃霅� 欤检嫕鞐� 雽�頃� 雼弲 鞚橁舶甓岅臣 雼弲 觳橂秳甓岇潉 氤挫湢頃橁碃 鞛堨溂氅� 鞝滌稖鞛愲ゼ 韴瀽鞛愲靷� (IA)搿� 鞁濍硠頃滊嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖鞛愲姅 頃措嫻 歃濌秾鞚� 韱奠儊鞝侅澑 鞓侅梾 瓿检爼鞐愳劀 氤挫湢霅橁碃 鞛堨溂氅� 氚滍枆須岇偓鞚� 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼鞚� 氙胳箻旮� 鞙勴暅 氇╈爜鞚� 鞎勲嫎鞚� 歃濍獏頃╇媹雼�. 歆�攵勳澊 5% 氙鸽鞚措瘈搿� 鞚� Schedule 13G/A電� Exchange Act鞐� 霐半ジ 靾橂彊鞝� 牍勳氚� 瓿店皽毳� 氚橃榿頃╇媹雼�.
MPM BioImpact LLC d茅clare la propri茅t茅 b茅n茅ficiaire de 5,622,505 actions ordinaires de Compass Therapeutics, soit 4.1% de la cat茅gorie. Le d茅p么t indique que la personne d茅clarant d茅tient le pouvoir de vote exclusif et le pouvoir de disposition exclusif sur les actions d茅clar茅es et identifie le d茅posant comme conseiller en investissements (IA). Le d茅posant certifie que les titres sont d茅tenus dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contr么le de l'茅metteur. 脡tant donn茅 que la participation est inf茅rieure 脿 5%, ce Schedule 13G/A constitue une divulgation passive sans contr么le en vertu de l'Exchange Act.
MPM BioImpact LLC meldet wirtschaftliches Eigentum an 5,622,505 Aktien der Stammaktien von Compass Therapeutics, entsprechend 4.1% der Klasse. Die Meldung besagt, dass die meldende Person alleinige Stimmrechte und alleinige Verf眉gungsmacht 眉ber die gemeldeten Aktien besitzt und identifiziert den Einreicher als Investmentberater (IA). Der Einreicher best盲tigt, dass die Wertpapiere im normalen Gesch盲ftsverlauf gehalten werden und nicht dazu dienen, die Kontrolle des Emittenten zu 盲ndern oder zu beeinflussen. Da die Beteiligung unter 5% liegt, stellt dieses Schedule 13G/A eine passive, nicht-kontrollierende Offenlegung nach dem Exchange Act dar.
FAQ
How many Compass Therapeutics (CMPX) shares does MPM BioImpact LLC report owning?
What percentage of CMPX does the reported holding represent?
Does MPM BioImpact claim voting or dispositive power over the shares?
What type of filer is MPM BioImpact LLC identified as?
Does the filing indicate the stake is intended to change control of Compass Therapeutics?
Is the reported ownership above the 5% reporting threshold?
